The U.S. government continues to ignore the crucial role of American scientists, institutions, and companies in creating the virus that causes COVID-19.
Author’s Note: The following is Chapter 1 in a four-part series about the true origin of SARS-CoV-2, the causative agent of COVID-19 illness. Chapters 2 and 3 have already been posted (see links below). Chapter 4: Ending the Great Charade/ A New Path to Truth & Justice, remains a work in progress.
The U.S. agencies that supported the development of the biotechnology—most notably USAID and the NIH—want the story to go away. Other institutions and people who participated in the cover-up—who insisted that the Lab Leak Hypothesis was a wild conspiracy theory—also want this story to go away. (See link for article)
Following a months-long investigation, local and federal officials uncovered a secret biotech lab with nearly 1,000 mice and 20 potentially infectious agents, according to authorities.
Fresno County authorities discovered an “unlicensed laboratory” inside a warehouse in Reedley, California. The secret lab was owned by Prestige BioTech – a company registered in Las Vegas, Nevada. Prestige BioTech claimed it moved assets to the warehouse from the now-defunct Universal Meditech Inc.
On March 3, a code enforcement officer reportedly noticed a garden hose attached and coming out of a wall in the back of the warehouse.
Reedley City Manager Nicole Zieba told KSEE, “Frankly, we knew that should not have been there and when she went to investigate, she found that there was activity or operation or something happening within that building.”
The Fresno County Public Health Department obtained search warrants and made the shocking discovery on March 16.
“Certain rooms of the warehouse were found to contain several vessels of liquid and various apparatus,” court documents stated. “Fresno County Public Health staff also observed blood, tissue and other bodily fluid samples and serums; and thousands of vials of unlabeled fluids and suspected biological material.”
(See link for article)
___________________
**Comment**
Why send money overseas when you can just send it down the street via U.S.P.S.?
According to Fresno County authorities, they found hundreds of mice bioengineered “to catch and carry the COVID-19 virus.”
Go here for Dr. Judy Mikovitz’s explanation of this mysterious lab. She first gives a history of her own take down by Dr. Fauci for discovering a mouse retrovirus in vaccines that cause chronic illness. Dr. Mikovits says the company behind the biolab is not Chinese. The fact the lab is located next to a U.S. military base is nothing new and that the samples in the lab came from Reno, Nevada.
The FBI likely raided the lab to cover up and control the narrative.
A few points:
The medical industrial complex knows the public is now watching their every move and no longer trusts them.
Tony Fauci knew the blood supply was contaminated but called it “chronic lyme disease” instead.
Forces within the American government are responsible for biolabs located across the nation.
The biolab in Fresno was storing the cell lines that had been isolated from people with diseases like cancer and autism.
American taxpayer dollars have been used to create pathogens that have been released onto the public.
This was done to make the public life long customers of Big Pharma.
Another important point here is the discovery of malaria. Please go here to learn how Spanish researchers point out that interstitial pneumonia & Acute Respiratory Distress Syndrome (ARDS) are not causing the death of COVID patients, which proves why ventilators have killed up to 70% of patients. These patients are really suffering from disseminated intravascular coagulation (DIC) – a medical term for blood clotting causing a lack of oxygen. The mRNA shots have also caused thrombocytopenia and microscopic blood clots that will build over time and explain the frightening clots embalmers are finding in the deceased who were “vaccinated,” as well as all the cases of myocarditis.
Guess what else causes hypercoagulation/thrombosis/blood clotting? Yep. Malaria.
Cite this article as: Weiler N S, Niendorf E, Dumic I (June 10, 2023) Two Insects, Two Bites, One Patient: A Lyme Disease and Jamestown Canyon Co-infection. Cureus 15(6): e40222. doi:10.7759/cureus.40222
Abstract
Lyme disease (LD) is the most common tick-borne illness across the United States, caused by the bacterium Borrelia burgdorferi sensu lato and transmitted to humans by the bite of infected Ixodes ticks. Jamestown Canyon Virus (JCV) is an emerging mosquito-borne pathogen found mostly in the upper Midwest and Northeastern United States. Co-infection between these two pathogens has not been previously reported since it would require the host to be bitten by the two infected vectors at the same time. We report a 36-year-old man who presented with erythema migrans and meningitis. While erythema migrans is a pathognomonic sign of early localized Lyme disease, Lyme meningitis does not occur in this stage but in the early disseminated stage. Furthermore, CSF tests were not supportive of neuroborreliosis, and the patient was ultimately diagnosed with JCV meningitis. We review JCV infection, LD, and this first reported co-infection to illustrate the complex interaction between different vectors and pathogens and to emphasize the importance of considering co-infection in people who live in vector-endemic areas.
This film explores bacterial biofilm infections and how they cause debilitating illnesses for tens of millions of Americans. People with “sub-clinical infections” suffer for months, years or even decades; others will lose life or limb because of the failure to treat chronic wounds or hospital acquired infections. More than 550,000 patients lose their lives annually because of hospital infections and twice that number will acquire sepsis. The majority of hospital infections involve bacterial biofilms and affect every area of specialized medicine and every part of the human body.
Paradoxically, the applications of biofilm eradication methods are slow to propagate into the many silos of western medicine. With patients and doctors in the dark about what is truly causing chronic diseases, millions of people remain undiagnosed and are denied effective treatments for their medical problems.
This ground-breaking documentary explores a new disease model on a scientific and human level. This film leverages interviews from top clinical experts with patients affected by bacterial biofilms to reach as wide an audience as possible. By breaking down complex topics of biofilm infections to a human level, showing staggering statistics, and using high quality animations, the message becomes accessible, compelling and obvious: biofilm infections are a gargantuan problem that has been overlooked by American society, and we as a nation are paying a terrible price.
However, with the advent of new molecular diagnostics, and a new way to understanding disease, Americans can effectively catalyze credible healthcare change by sharing this information that helps eliminate needless suffering, save lives and reduce the costs of health care.
John G. Thomas, MS, Ph.D. International Educator and Global Microbiologist Professor, WVU Dept. of Pathology, School of Medicine Clinical Professor, WVU Dept. of Periodontics, School of Dentistry Director(s) WVU High Complexity Laboratory & Biofilm Research Laboratory for Translational Studies
J. William Costerton, Ph.D. “The Father of Biofilms” Director, Microbial Research, Department of Orthopedics, Allegheny General Hospital Director, Biofilm Research, Center for Genomic Sciences, Allegheny-Singer Research Institute
Dr. Randy Wolcott, MD CWS Medical Director, Southwest Regional Woundcare Center Founder, Pathogenius Laboratories Timothy K. Lu, M.D., Ph.D. Assistant Professor Synthetic Biology Group MIT Department of Electrical Engineering and Computer Science MIT Synthetic Biology Center
Wilmore C. Webley, Ph.D. Assistant Professor Department of Microbiology University of Massachusetts Amherst
Vincent A. Fischetti, Ph.D. Professor and Chairman Laboratory of Bacterial Pathogenesis and Immunology The Rockefeller University
Michael Wilson, GRSC, MSc, PhD, DSc, FRCPath Professor of Microbiology Eastman Dental Institute, University College London
David C. Kennedy, DDS Past President International Academy of Oral Medicine and Toxicology
Doyle Williams, DDS Chief Dental Officer Delta Dental of Massachusetts
Eva Sapi Ph.D. Associate Professor and University Research Scholar Director of Lyme Disease Program Department of Biology and Environmental Science University of New Haven
Rodney M. Donlan, Ph.D. Research Microbiologist Biofilm Laboratory Clinical and Environmental Microbiology Branch Centers for Disease Control and Prevention
L. Clifford McDonald, MD Senior Advisor for Science and Integrity Division of Healthcare Quality Promotion Centers for Disease Control and Prevention
Shirley Gutkowski, RDH, BSDH, FACE Oral Healthcare Expert Founding Member American Academy of Oral Systemic Health
Trisha E. O’Hehir, RDH, MS Editorial Director of Hygienetown Magazine President of Perio Reports Press
Nicolas G. Loebel, Ph.D. Chief Technology Officer & President Ondine Biomedical Inc.
Kris Koss, D.V.M. Doctor of Veterinary Medicine Carlene Patterson, D.V.M. Doctor of Veterinary Medicine Sheep Meadow Animal Hospital Thomas Webster, Ph.D. Associate Professor Division of Engineering and Orthopedic Surgery Director of Nanomedicine Laboratory Brown University
Carolyn Cross Chairman and Chief Executive Officer Ondine Biomedical, Inc.
Steve Holland, MD Chief, Laboratory of Clinical Infectious Diseases Chief, Immunopathogenesis Section National Institute of Allergy and Infectious Diseases
Garth D. Ehrlich, Ph.D. Executive Director, Center for Genomic Sciences Allegheny-Singer Research Institute
John P. Kennedy, R. Ph., Ph.D Assistant Professor South University, School of Pharmacy Savannah, Georgia
Dr. “Lon” H. Jones, D.O Retired Osteopathic Family Physician Founder, Xlear, Inc. Author, No More Allergies, Asthma or Sinus Infections Tom Masterson Operations Manager Ondine Biomedical, Inc.
Scot E Dowd, Ph.D. Molecular Microbiologist & Microbial Geneticist Molecular Research LP
CHRONIC LYME DISEASE PATIENTS WANT TO BE TREATED, NOT ‘MANAGED’ BY PHYSICIANS
Over the past month, a series of articles, focusing on multiple aspects of Lyme disease, from pediatric Lyme to chronic Lyme to life after Lyme, have been published in the May and June issues of Infectious Disease Clinics of North America and Clinical Infectious Diseases. The articles echo messages that, for the most part, minimize a disease that impacts hundreds of thousands of people each year — many of whom are children.
“Minds are like parachutes. They only function when open.” This particular quote by Thomas Dewar came to mind after reading an article, Chronic Lyme Disease (1) in the June issue of Infectious Disease Clinics of North America.
In it, the author writes, “the scientific community has largely rejected chronic, treatment-refractory Borrelia burgdorferi infection.” This is based on “the failure to detect cultivatable, clinically relevant organisms after standard treatment.”
The intention of the Chronic Lyme Disease article is evident — convince readers that chronic Lyme disease does not exist, and that antibiotics prescribed for more than 14- to 28-days are of no benefit and most patients have no lingering symptoms.
It is particularly troublesome that the author, Paul Lantos, MD, a Duke University Medical Center researcher, is co-chair on a panel responsible for updating the Infectious Disease Society of America’s (IDSA) treatment guidelines for Lyme disease. Dr. Lantos holds a position not to be taken lightly. The IDSA recommendations will determine, for the most part, the types of treatment patients diagnosed with Lyme disease will receive.
Additionally, Dr. Lantos includes a section entitled, “Clinical Approach to Patients with Chronic Lyme Disease Diagnosis,” in which he offers suggestions to physicians on how to ‘manage’ patients complaining they have chronic Lyme disease.Recommendations include listening patiently during the consultation and then explaining to the patient why their symptoms are not related to Lyme disease.
“…a certain amount of time must be spent reviewing past experiences and past laboratory tests … then explaining why Lyme disease may not account for their illnesses.”
“Even if chronic Lyme disease lacks biological legitimacy, its importance as a phenomenon can be monumental to the individual patient,” says Lantos. “Many have undergone frustrating, expensive, and ultimately fruitless medical evaluations. And many have become quite disaffected with a medical system that has failed to provide answers.”
Managing patients, who insist they have chronic Lyme disease can be challenging, he warns. This subset of patients can have “great variation in their ‘commitment’ to a chronic Lyme disease diagnosis. Some patients are entirely convinced they have chronic Lyme disease, they request specific types of therapy, and they are not interested in adjudicating the chronic Lyme disease diagnosis.”
Should a clinician have a patient who believes they have chronic Lyme disease, there are several ways to manage the evaluation, he explains. First, “the physician needs to suppress preconceptions or biases about such patients.”
Second, “the process of clinical information gathering in medicine … is no different in the context of chronic Lyme disease. Even if much discussion is centered on chronic Lyme disease.”
And, lastly, “it is of utmost importance to not seem to be impatient, dismissive, or rushed. Many patients who seek care for chronic Lyme disease already have accumulated frustration. … Each patient’s clinical story and personal history is unique and valid, even if one concludes that they do not have Lyme disease.”
For the patients who do remain chronically symptomatic, Dr. Lantos explains, there has been “little evidence of active infection, and their symptoms do not respond to antibiotics any better than to placebo.”
When dealing with complex, chronic illnesses, physicians need to develop a trusting and understanding relationship with their patients. It is impossible for a clinician to provide the highest level of care to their patients, which includes a thorough evaluation, if they enter into the doctor-patient relationship with preconceived notions, not only about an extremely complex disease but about the patient who is reporting the symptoms, which are often subjective.
Should the patient not have any of the three objective signs of Lyme disease — the bulls-eye rash, swollen knee and/or Bell’s Palsy, identifying the infection is dependent on a strong evaluation. Patients want physicians to provide effective treatments. They don’t want to be ‘managed.’
It is time for a new narrative. One that recognizes the complexity of the Lyme spirochete and acknowledges the ineffective simplicity of the ‘one-size fits all’ treatment approach.
Also, it’s imperative to point out that coinfections are rarely taken into consideration, yet chronically infected patients are notoriously coinfected with other pathogens. The fact they don’t improve is most probably due to the fact they are not treating these coinfections which can be as bad if not worse than Lyme. Bartonella and Babesia are two such pathogens that can knock you off your feet but require very different medications than Lyme meds. This is simply never discussed.
My husband and I are two chronically infected patients that have improved vastly with extended antimicrobial treatment. Without this treatment, I’m not sure either of us would be alive. I know many others in this boat as well. We don’t make the research papers because none of us fit the criteria to even enter a study:
These parameters that continue to be used will continue to give a preconceived outcome: no chronic/persistent infection. It’s circular reasoning of the worst kind that hasn’t budged in over 40 years.
The experiments would see some of the prisoners injected with infected lung tissue from sick or deceased patients, have infected tissue dropped in their eyes, and sprayed in the nose and mouth with infectious aerosols. Others would see mucus taken from critically ill patients and put it into the noses and throats of prisoners. In other parts of the trials, experimenters would take the blood of the sick and inject it into the healthy, to see if it was spread through infectious microorganisms in the blood.
As well as the various fluid exchanges mentioned above, a further part of the experiments saw ten healthy prisoners taken into a hospital for patients who were dying of the disease. There, they were asked to stand over the sick and dying, lean over their faces and breathe in heavily while they exhaled. Just to be sure of exposure, the flu patients would cough into the face and mouths of the prisoners.
Guess what? Not a single patient in the experiment died of the disease – they didn’t even become ill.
Ponder this for a moment.
I mean, what is the likelihood?
Yet, despite this fact, we are told that the Spanish Flu is the most deadly virus on the planet.
According to manyexperts, this lack of proof of viral infectivity is a big deal but has resulted in a massively lucrative “vaccination” program that only worsens with time – now forcing people to concede to these injections or lose their jobs.
Meanwhile, back in Lymeland, lack of definitive proof stops the show. Experts claim, “If we can’t see it, smell it, touch it, it doesn’t exist.”
Anyone with half a brain would see this comparison and acknowledge that something is truly rotten in Denmark.
Madison Area Lyme Support Group 